|Mr. Ãystein Soug||Chief Exec. Officer||3.65M||N/A||1969|
|Mr. TorbjÃ¸rn Furuseth||Chief Financial Officer||2.58M||N/A||N/A|
|Dr. Victor Levitsky M.D., Ph.D.||Chief Scientific Officer||1.82M||N/A||N/A|
|Dr. Magnus JÃ¤derberg||Chief Medical Officer||4.23M||N/A||N/A|
|Mr. Erik Digman Wiklund||Chief Bus. Officer||2.51M||N/A||N/A|
|Dr. Kirsi Hellstrom||Head of CMC||958k||N/A||N/A|
|Ms. Ingunn Munch Lindvig||VP of Regulatory Affairs||1.54M||N/A||N/A|
|Mr. Jon Amund Eriksen M.Sc., MSc||Special Advisor||N/A||N/A||N/A|
|Prof. Gustav Gaudernack Ph.D.||Chief Scientific Adviser||N/A||N/A||N/A|
|Dr. Peter Skorpil Ph.D.||VP of Bus. Devel.||N/A||N/A||N/A|
Targovax ASA, a clinical stage immuno-oncology company, engages in the development of immune activators to target hard-to-treat solid tumors. Its lead product candidate is ONCOS-102, which is in Phase I/II clinical studies for the treatment of mesothelioma, melanoma, and colorectal cancer. The company is also developing neoantigen cancer vaccines targeting tumors with oncogenic RASÂmutations. In addition, it is developing ONCOS-211 for next generation ONCOS viruses. The company has collaboration agreements with Cancer Research Institute and Ludwig Cancer Research to develop ONCOS-102 for colorectal cancer with peritoneal carcinomatosis; Valo Therapeutics to develop mutant RAS neoantigen coating of ONCOS viruses using PeptiCRAd technology; and Papyrus Therapeutics to develop novel ONCOS viruses with Receptor Tyrosine Kinase inhibitor functionality. Targovax ASA was incorporated in 2010 and is based in Lysaker, Norway.
Targovax ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.